Botulinum Toxin Market - Global
Insights, and Forecast till 2026
Industry
Botulinum toxin is a product produced by naturally occurring Clostridium botulinum bacteria.
This bacteria is found in soil and marine sediments and can produce harmful neurotoxin
botulinum toxin. Botulinum toxin is a ‘blocking agent’ which inhibits the release of certain
neurotransmitters, specifically acetylcholine, from the endings of the motor nerves. There are
about eight types of botulinum toxin named from type A to H. Botulinum toxin type A and
botulinum toxin type B are majorly used in cosmetic procedures for the treatment of various
facial conditions, its commercially marketed under the brand name Botox. Botulinum toxin type
A and B are also used in medical applications for treatment of various diseases such as
dystonia, chronic migraines, and spasticity.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/1518
Botulinum Toxin Market: Drivers
Frequent approvals of novel botulinum toxin products for different indications are expected to
drive growth of the Botulinum Toxin Market in near future. For instance, in 2016, Ipsen S.A.
received the U.S. Food and Drug Administration (FDA) approval for its Dysport
(abobotulinumtoxinA) injection indicated for the treatment of pediatric lower limb (PLL)
spasticity in children of age two years and older. In 2017, company received the FDA approval
for same product to use in adults. In 2017, Allergan plc. received FDA approval for BOTOX
Cosmetic (OnabotulinumtoxinA) for new indication in forehead lines, and previously the product
has been approved for the treatment of , crow's feet lines, and glabellar lines. With this
approval company has expanded the indication of its product in the temporary improvement in
the appearance of moderate to severe forehead lines associated with frontalis muscle activity in
adults. In 2014, Allergan Inc. received approval for its BOTOX (Botulinum toxin type A) from
Medicines and Healthcare Products Regulatory Agency (MHRA) in U.K. BOTOX was approved in
the U.K. for treatment of ankle disability due to lower limb spasticity associated with stroke in
adults. In 2016, Daewoong Pharmaceutical Co., Ltd received approval for its botulinum toxin
Nabota in Mexico and India. Nabota was introduced by Daewoong Pharmaceutical Co., Ltd in
South Korea in 2014. In 2015, Merz North America, the U.S. subsidiary of the global Merz
Pharma Group, received U.S. FDA approval for Xeomin (incobotulinumtoxinA) indicated for the